Metabolic Dysfunction-associated Steatotic Liver Disease

The central purpose of the Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG (formerly the NAFLD SIG) is to provide a forum to share ideas, foster collaboration and brainstorm together as an academy of basic and translational investigators. Our mission is to study the pathogenesis, diagnosis, natural history and development of therapeutics for metabolic dysfunction-associated steatotic Liver disease. The MASLD SIG sponsors programs at the AASLD Annual Meeting, identifies emerging topics in MASLD, and supports the educational mission of AASLD. policy.

SIG Leadership

Chairs
Mazen Noureddin, MD, MHSc
Alina M. Allen, MD
Associate Lead
Jessica Bartholomew, NP
Communication Lead
Pinelopi Manousou
Education Lead
Robert J. Fontana, MD, FAASLD
Trainee Lead
Maria Mironova, MD
SIG Steering Committee Members
Grace L. Guo, FAASLD
Yaron Rotman, MD, MSc, FAASLD
Advanced Transplant/Hepatology Awardee
Stefani Tica, MD, MPH
Staff Liaisons
Akuender Dot, MPH
Julie Hoffman, MBA
Emerging Liver Advanced Practice Provider Program Awardee
Kristy Kiermaier, NP